MacroGenics Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
MacroGenics Bundle
Visual. Strategic. Downloadable.
Curious about MacroGenics' product portfolio? Our BCG Matrix analysis highlights which products are driving growth (Stars), generating consistent revenue (Cash Cows), lagging behind (Dogs), or present potential but require more investment (Question Marks). This snapshot offers valuable directional insight.
To truly unlock the strategic advantage, purchase the full BCG Matrix report. It provides granular data, detailed quadrant placements, and actionable recommendations to optimize your investment and product development strategies for MacroGenics.
Don't miss out on the complete picture. Get the full BCG Matrix and gain a clear, data-driven understanding of MacroGenics' market position, enabling you to make informed decisions and outmaneuver the competition.
Stars
Lorigerlimab (mCRPC)
Lorigerlimab, a bispecific PD-1 × CTLA-4 DART molecule, is currently being evaluated in the fully enrolled Phase 2 LORIKEET study for metastatic castration-resistant prostate cancer (mCRPC). Clinical updates are expected in the latter half of 2025, offering a key data point for its market potential.
Given the historical challenges in treating mCRPC, lorigerlimab's advancement in this setting indicates significant growth potential. The drug's success could establish it as a prominent therapy, capitalizing on MacroGenics' advanced DART technology.
Lorigerlimab (Ovarian Cancer)
Lorigerlimab is being explored in the LINNET Phase 2 study for platinum-resistant ovarian cancer and clear cell gynecologic cancer, with patient dosing commencing mid-2025. This move targets a significant unmet need in oncology.
The potential for lorigerlimab in ovarian cancer, a disease with a 5-year survival rate of approximately 30% in its advanced stages, represents a substantial market opportunity. Positive early results from the LINNET study could position this DART asset for considerable future market share and growth within this critical therapeutic area.
MGC026 (B7-H3 ADC)
MGC026 is a promising antibody-drug conjugate (ADC) targeting B7-H3, currently in Phase 1 clinical trials with dose escalation underway. MacroGenics is planning dose expansion for MGC026 in 2025, demonstrating a strategic commitment to this therapeutic approach.
The company's continued focus on MGC026, even after discontinuing vobra duo, underscores a strong conviction in the significant growth potential of targeting B7-H3. This target is believed to be effective across a range of solid tumors, making MGC026 a key asset in MacroGenics' pipeline.
MGC028 (ADAM9 ADC)
MGC028, an antibody-drug conjugate targeting ADAM9, is currently navigating Phase 1 clinical trials. This early-stage development places it within MacroGenics' expanding portfolio of ADCs, a class of therapeutics experiencing significant growth in the oncology market.
The focus on solid tumors for MGC028 is strategic, as this represents a vast and largely underserved patient population. Success in these trials could unlock substantial market opportunities for MacroGenics. For instance, the global oncology market was valued at over $200 billion in 2023 and is projected to continue its upward trajectory.
- MGC028 targets ADAM9, a protein implicated in tumor growth and metastasis.
- Currently in Phase 1 clinical development for solid tumors.
- Represents a key asset in MacroGenics' growing ADC pipeline.
- Positive clinical outcomes could lead to significant market penetration in a high-growth therapeutic area.
Proprietary DART Platform
MacroGenics' proprietary DART platform is a cornerstone of its high-growth strategy, enabling the development of innovative bispecific antibodies designed for enhanced therapeutic efficacy.
This platform is a key driver for generating a pipeline of novel product candidates with significant breakthrough potential in oncology. MacroGenics has consistently invested in advancing its DART technology, recognizing its capacity to unlock new treatment paradigms.
The DART platform's ability to create bispecific antibodies allows for simultaneous targeting of multiple tumor-associated antigens or immune cells, thereby enhancing anti-tumor activity and potentially overcoming resistance mechanisms. This technological advantage positions MacroGenics to capture substantial future market share across a range of oncology indications.
- DART Platform: Enables bispecific antibody development for enhanced oncology treatments.
- Pipeline Generation: Drives the creation of novel product candidates with breakthrough potential.
- Market Capture: Positions MacroGenics to secure future market share in diverse oncology indications.
- Investment Focus: Continuous investment fuels platform advancement and new therapeutic opportunities.
MacroGenics' Pipeline: High-Potential Oncology Assets
Lorigerlimab, targeting mCRPC and ovarian cancer, and MGC026, an ADC for solid tumors, represent MacroGenics' key "Stars" due to their significant market potential and ongoing clinical development. MGC028, another ADC in early trials, also shows promise in a high-growth area.
These assets leverage MacroGenics' DART and ADC technologies, positioning them for substantial future market capture. The global oncology market's continued growth, exceeding $200 billion in 2023, underscores the opportunity for successful therapies.
| Product | Target Indication | Platform | Development Stage | Market Potential |
|---|---|---|---|---|
| Lorigerlimab | mCRPC, Ovarian Cancer | DART | Phase 2 | High |
| MGC026 | Solid Tumors | ADC (B7-H3) | Phase 1 | High |
| MGC028 | Solid Tumors | ADC (ADAM9) | Phase 1 | Significant |
What is included in the product
Detailed Word Document
The MacroGenics BCG Matrix analyzes its product portfolio by classifying units as Stars, Cash Cows, Question Marks, or Dogs.
Customizable Excel Spreadsheet
MacroGenics BCG Matrix offers a clear, one-page overview of its product portfolio, simplifying strategic decision-making by placing each business unit in its appropriate quadrant.
Cash Cows
Retifanlimab (ZYNYZ®) Milestones and Royalties
MacroGenics' licensing agreement for Retifanlimab (ZYNYZ®) with Incyte positions it as a strong Cash Cow within their BCG Matrix. This partnership has already yielded substantial financial benefits, with MacroGenics receiving a significant $100 million milestone payment in July 2024. This payment was triggered by positive Phase 3 clinical trial results, underscoring the drug's development progress.
The ZYNYZ® collaboration is structured to provide ongoing, high-margin revenue streams for MacroGenics. Beyond the recent milestone, the company is eligible for further development, regulatory, and commercial milestones. Additionally, MacroGenics will benefit from tiered royalties on future sales, all without incurring the direct costs associated with commercializing the product themselves.
TZIELD® (Teplizumab) Milestones
TZIELD, a monoclonal antibody developed by MacroGenics and sold to Sanofi, received FDA approval in November 2022 for its potential to delay the onset of type 1 diabetes. This approval positions TZIELD as a significant revenue generator for MacroGenics.
MacroGenics is set to receive substantial remaining milestone payments from its agreement with Sanofi for TZIELD. This stream of non-dilutive income is a prime example of a cash cow, as it leverages past research and development with limited additional investment required from MacroGenics.
Contract Manufacturing Services
MacroGenics' contract manufacturing services are a clear Cash Cow, demonstrating robust growth. In Q2 2025, this segment generated $15.4 million in revenue, a significant leap from $2.9 million in Q2 2024. This substantial increase highlights the segment's ability to generate consistent and expanding cash flow.
This strong performance in contract manufacturing underscores its role as a stable cash generator for MacroGenics. The revenue stream effectively utilizes the company's existing manufacturing infrastructure, thereby bolstering financial stability and providing crucial funding for its research and development initiatives.
Strategic Partnership Income
MacroGenics' strategic shift towards partnership income positions its collaborations as key cash cows. The company has secured significant funding, including over $1.7 billion in potential milestone payments from major pharmaceutical partners like Gilead, Incyte, and Sanofi. This approach offers a stable financial base and a reliable income stream.
This partnership strategy effectively mitigates MacroGenics' direct financial exposure. By leveraging the resources and market reach of its collaborators, the company can maximize the potential returns from its innovative drug pipeline without bearing the full cost of late-stage development and commercialization.
- Partnership Revenue Model: Focus on collaborations for development and commercialization.
- Milestone Payments: Over $1.7 billion in potential milestone payments secured from key partners.
- Risk Mitigation: Reduced direct financial risk by sharing development and commercialization costs.
- Predictable Income: Creates a more stable and predictable revenue stream for the company.
Existing Cash Position and Runway
MacroGenics' existing cash position provides significant financial strength. As of June 30, 2025, the company reported $176.5 million in cash and cash equivalents. This robust liquidity is projected to sustain operations through the first half of 2027, offering a substantial runway for continued development.
This financial stability is a key component of its BCG Matrix, acting as a 'cash cow'. The strong cash position enables disciplined investment in promising programs, supporting ongoing research and development efforts.
- Cash Position: $176.5 million as of June 30, 2025.
- Projected Runway: Extended through the first half of 2027.
- Liquidity Drivers: Milestone payments and cost reduction initiatives.
- Strategic Role: Serves as a financial 'cash cow' for sustained operations and future development.
MacroGenics: Cash Cow Strategy Fuels Financial Stability
MacroGenics' licensing agreement for Retifanlimab with Incyte, along with the Sanofi collaboration for TZIELD, are prime examples of its Cash Cow strategy. These partnerships leverage past R&D investments to generate predictable, high-margin revenue streams through milestone payments and royalties, minimizing MacroGenics' direct commercialization costs.
The company's contract manufacturing services also significantly contribute to its Cash Cow status, showing remarkable year-over-year revenue growth. This segment capitalizes on existing infrastructure, providing stable cash flow that fuels further innovation and development.
MacroGenics' overall partnership model, aiming for over $1.7 billion in potential milestone payments, alongside a strong cash position of $176.5 million as of June 30, 2025, solidifies its Cash Cow assets. This financial stability ensures operational continuity and supports strategic investments.
| Asset | Revenue Source | Status | Key Financials |
| Retifanlimab (Incyte) | Milestone Payments & Royalties | Cash Cow | $100M milestone in July 2024 |
| TZIELD (Sanofi) | Milestone Payments & Royalties | Cash Cow | Significant remaining milestone payments |
| Contract Manufacturing | Service Revenue | Cash Cow | $15.4M revenue in Q2 2025 (vs $2.9M in Q2 2024) |
| Partnerships (Gilead, etc.) | Potential Milestones | Cash Cow Foundation | >$1.7B potential milestones |
| Cash & Equivalents | Working Capital | Financial Strength | $176.5M as of June 30, 2025 |
Full Transparency, Always
MacroGenics BCG Matrix
The BCG Matrix document you are currently previewing is the identical, fully formatted report you will receive immediately after your purchase. This means you'll gain access to the complete analysis without any watermarks or demo content, ready for immediate strategic application. You can trust that what you see is precisely what you'll download, enabling you to seamlessly integrate this powerful business tool into your planning and decision-making processes. This ensures a transparent and efficient acquisition of a valuable strategic resource.
Dogs
Vobramitamab duocarmazine (vobra duo)
Vobramitamab duocarmazine (vobra duo) has been classified as a 'Dog' within MacroGenics' portfolio. The company has ceased its internal clinical development, citing Phase 2 study results that did not justify further financial investment.
MacroGenics is now seeking potential partners to advance vobra duo, a B7-H3 targeting antibody-drug conjugate. This strategic move signals a divestiture, as the asset no longer aligns with the company's internal investment priorities.
MARGENZA® (margetuximab)
MARGENZA (margetuximab) has been divested, with MacroGenics selling its global rights to TerSera Therapeutics in November 2024. This strategic move indicates that MARGENZA, despite generating some sales, was not a primary growth driver or a high-profit asset for MacroGenics' long-term plans. The divestiture allows MacroGenics to shift its focus and resources towards developing its more promising pipeline candidates.
Discontinued Clinical Programs
MacroGenics has a history of discontinuing clinical programs to streamline its focus and manage resources effectively. For instance, in 2023, the company announced the termination of its Phase 2 study for MGC018 in prostate cancer, citing a strategic shift. This move, along with workforce reductions, aimed to concentrate on more promising assets.
These past decisions to cease internal development on specific programs highlight a pragmatic approach to pipeline management. Such terminations, while representing sunk costs, are crucial for reallocating capital and personnel toward initiatives with higher perceived potential for success and market impact. This strategy is common in the biopharmaceutical industry where R&D is inherently high-risk.
Enoblituzumab (Earlier Programs)
Enoblituzumab, an earlier program from MacroGenics, serves as a prime example of a 'Dog' within the BCG Matrix framework. Its Phase 2 study was discontinued in July 2022 following an unexpectedly high rate of fatal bleeding events.
This discontinuation, while not a recent development, underscores the significant risks inherent in biotechnology research and development. It demonstrates a scenario where substantial resources were invested in a program that ultimately lacked a viable path to market, necessitating the difficult decision to terminate and reallocate capital.
The situation with enoblituzumab highlights the critical need for biotech companies to rigorously assess and manage their product pipelines, cutting losses on assets that fail to demonstrate sufficient efficacy or safety.
- Program: Enoblituzumab
- Status: Phase 2 study discontinued July 2022
- Reason for Discontinuation: Unexpected high incidence of fatal bleeding
- BCG Matrix Classification: Dog
Legacy Non-Core Assets
Legacy Non-Core Assets in MacroGenics' portfolio represent programs that have not progressed significantly, often remaining in the preclinical or very early stages. These assets typically lack active development plans due to limited demonstrated promise for advancement or potential partnering opportunities. As of late 2024, MacroGenics continues to manage a pipeline where such assets require minimal ongoing investment.
These legacy assets are unlikely to contribute meaningfully to future growth or market share. Consequently, the company's strategy often involves maintaining them with very low expenditure or exploring out-licensing options at a nominal value. This approach allows MacroGenics to focus resources on more promising pipeline candidates.
- Minimal Investment: Legacy assets are maintained with reduced operational and research funding.
- Out-Licensing Potential: Opportunities for out-licensing are explored, often at low valuation.
- Limited Growth Prospects: These assets are not expected to drive significant future revenue or market penetration.
- Strategic Resource Allocation: Focus remains on advancing higher-potential pipeline candidates.
MacroGenics' Strategic Pipeline Adjustments
Vobramitamab duocarmazine (vobra duo) and enoblituzumab are classified as 'Dogs' in MacroGenics' BCG matrix, reflecting discontinued or divested assets with low market share and growth potential. The company's strategic decision to cease internal development for vobra duo, following unpromising Phase 2 results, and the earlier discontinuation of enoblituzumab due to safety concerns, exemplify this classification. These moves allow MacroGenics to reallocate resources to more promising pipeline candidates.
MacroGenics has actively managed its portfolio by divesting or discontinuing programs that do not align with its strategic growth objectives. The sale of MARGENZA in November 2024, along with prior terminations like the MGC018 Phase 2 study in 2023, underscores a disciplined approach to pipeline management. This strategy, while involving sunk costs, is crucial for optimizing capital and personnel allocation towards assets with higher perceived market potential and success rates.
Legacy non-core assets, often in preclinical or early stages, are maintained with minimal investment and potential out-licensing at nominal values. These assets, like those in the 'Dog' category, are not expected to contribute significantly to future revenue or market penetration. MacroGenics' focus remains on advancing its higher-potential pipeline candidates, a common and prudent strategy in the high-risk biotechnology sector.
| Asset | BCG Classification | Status/Reason | Date/Year | Strategic Implication |
|---|---|---|---|---|
| Vobramitamab duocarmazine | Dog | Internal development ceased; seeking partners | 2024 | Reprioritization of R&D focus |
| Enoblituzumab | Dog | Phase 2 study discontinued; fatal bleeding events | July 2022 | Risk management, capital reallocation |
| MARGENZA | Divested (likely Dog or Cash Cow transitioning) | Global rights sold to TerSera Therapeutics | November 2024 | Streamlining portfolio, focus on core pipeline |
| MGC018 | Discontinued (likely Dog) | Phase 2 study terminated; strategic shift | 2023 | Resource optimization, focus on core pipeline |
Question Marks
MGD024 (CD123 x CD3 DART)
MGD024, a promising CD123 x CD3 DART molecule, is currently undergoing Phase 1 dose escalation for CD123-positive cancers, including hematologic malignancies. Gilead holds an option to license this asset, indicating potential future commercialization.
As an early-stage development candidate, MGD024 targets high-need areas like Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). While the potential market is significant, its market share remains unproven, reflecting substantial future investment needs or strategic partnerships.
MGC030 (Undisclosed ADC)
MGC030, an antibody-drug conjugate with an undisclosed target, is positioned as a Question Mark in MacroGenics' BCG Matrix. Its preclinical status means it has significant future growth potential in the burgeoning ADC market, a sector projected for substantial expansion.
The company plans to file an Investigational New Drug (IND) application for MGC030 in 2026. While this signifies a critical step towards market entry, the asset currently has no market share and necessitates considerable research and development investment to validate its efficacy and commercial viability.
LINNET Phase 2 Study of Lorigerlimab (Ovarian Cancer)
The LINNET Phase 2 study of lorigerlimab in platinum-resistant ovarian cancer and clear cell gynecologic cancer positions this drug as a potential 'Question Mark' for MacroGenics. This new indication requires substantial investment to prove its efficacy and capture market share, a crucial step in determining its future growth potential.
Future DART and ADC Innovations
MacroGenics' commitment to its DART platform and novel antibody-drug conjugate (ADC) technologies represents a significant investment in its future pipeline. These early-stage or preclinical efforts are inherently high-risk, high-reward, demanding substantial research and development expenditure.
The company's ongoing investment in these areas aims to identify and develop breakthrough products capable of securing substantial market positions. For instance, in 2023, MacroGenics reported R&D expenses of $213.5 million, a portion of which is allocated to these forward-looking initiatives.
- DART Platform Enhancement: Continued refinement of the DART technology to improve efficacy and safety profiles of bispecific antibodies.
- Novel ADC Targets: Exploration and validation of new target antigens for ADC development, expanding the therapeutic potential beyond current indications.
- Preclinical Pipeline Expansion: Progression of very early-stage ADC candidates through preclinical studies, aiming for IND-enabling studies.
- Strategic Partnerships: Potential collaborations to leverage external expertise and accelerate the development of these innovative platforms.
Combination Therapies (e.g., Vobra duo + Lorigerlimab)
MacroGenics is exploring combination therapies, specifically vobra duo with lorigerlimab, which positions them within a dynamic segment of the BCG matrix. While vobra duo as a standalone treatment might be considered a 'Dog' due to its current market standing, its integration with lorigerlimab signifies a strategic shift towards potential high-growth areas.
This combination therapy is currently undergoing a Phase 1/2 dose escalation study across several advanced solid tumors. The objective is to evaluate the safety and efficacy of this pairing, aiming to establish a foothold in a market where its share is yet to be defined.
- Vobra duo as monotherapy: Currently classified as a 'Dog' in the BCG matrix.
- Combination with Lorigerlimab: Represents a 'Question Mark' due to its high growth potential and unestablished market share.
- Phase 1/2 Study Enrollment: Ongoing for vobra duo plus lorigerlimab in advanced solid tumors.
- Strategic Focus: Investing in this combination aims to assess and potentially capture future market opportunities.
Unlocking Future Growth: High-Potential Assets
Question Marks represent MacroGenics' early-stage assets with high growth potential but no current market share. These require significant investment to advance through development and clinical trials. Successful progression could lead to future market leadership.
MGC030, an ADC, and lorigerlimab in new indications are prime examples, with IND filings planned for 2026 and ongoing studies respectively. The company's R&D spending, which was $213.5 million in 2023, reflects the substantial capital needed for these ventures.
The combination therapy of vobra duo with lorigerlimab also falls into this category, aiming to carve out a future market share. These investments are crucial for MacroGenics' long-term pipeline development and market positioning.
| Asset | Stage | Market Share | Growth Potential | Investment Needs |
|---|---|---|---|---|
| MGC030 | Preclinical | None | High | High |
| Lorigerlimab (New Indications) | Phase 2 | None | High | High |
| Vobra duo + Lorigerlimab Combo | Phase 1/2 | None | High | High |